Metformin-letrozole in comparison with metforminclomiphene citrate in clomiphene-resistance PCOS patients undergoing IUI

ABSTRACT

Polycystic ovary syndrome [PCOS] is associated with approximately 75% of women who suffer from infertility due to anovulation. Additionally, around 20-25% of anovulatory women with PCOS do not respond at all to clomiphene citrate and are considered to be "clomiphene-resistant". Aromatase inhibitors have been suggested as an alternative treatment to clomiphene as the discrepancy between ovulation and pregnancy rates with clomiphene citrate has been attributed to its anti-estrogenic action and estrogen receptor depletion. The aim of this study is to compare results of Metformin-letrozole with Metformin-clomiphene citrate in clomiphene resistance PCOS patients undergoing IUI. In this single blind randomized trial, ovarian cycles were studied in 100 clomiphene- resistant patients with PCOS. The inclusion criteria were patients who received 150mg clomiphene citrate daily for 3 cycles and failed to become pregnant. The patients were matched for their age, body mass index [BMI], and infertility period. They were randomly allocated to a metformin-letrozole group [n=50] and a metformin-clomiphene citrate group [n=50]. Chemical and clinical pregnancies were assessed after IUI. Abortion rates were determined in both groups. Regarding pregnancy rate, there was no significant difference between the two groups. One miscarriage [2%] occurred in the metformin-clomiphene citrate group, whereas none was seen in the metformin-letrozole group. There is no significant difference in pregnancy rate between clomiphene citrate and letrozole groups although it has been 2% in the former and 5% in the latter